Office-based management of opioid dependence with buprenorphine: clinical practices and barriers
about
2012 Update in addiction medicine for the generalistUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceUpdate on Barriers to Pharmacotherapy for Opioid Use Disorders.Improving temporal efficiency of outpatient buprenorphine induction.Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trialCost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial.Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experienceImplementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.Update in addiction medicine for the generalistBuprenorphine implant for opioid addictionGeographic and specialty distribution of US physicians trained to treat opioid use disorder.Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centersThe prescription of addiction medications after implementation of chronic care management for substance dependence in primary carePreliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency.Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.Access to Addiction Pharmacotherapy in Private Health Plans.Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural CountiesBuprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment OrganizationsHuman immunodeficiency virus testing practices among buprenorphine-prescribing physiciansA multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatmentGrowth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11Factors associated with complicated buprenorphine inductionsA contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.Using a Learning Collaborative Strategy With Office-based Practices to Increase Access and Improve Quality of Care for Patients With Opioid Use Disorders.Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?Home buprenorphine/naloxone induction in primary careConfidentiality protections versus collaborative care in the treatment of substance use disordersA buprenorphine education and training program for primary care residents: implementation and evaluation.Teaching and assessing residents' skills in managing heroin addiction with objective structured clinical examinations (OSCEs)A qualitative study of the adoption of buprenorphine for opioid addiction treatment.Barriers to primary care physicians prescribing buprenorphine.Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.A case series of buprenorphine/naloxone treatment in a primary care practice.Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: A feasibility study.The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
P2860
Q26864774-DD7528C1-9810-4C5B-91EF-1A21938B7EE7Q26865674-608EE3AD-3C7F-404B-9F76-1C49165BD2A7Q30234408-7DB153CC-C3F4-446A-B0EF-8BFA9988992EQ30425074-BC917B59-08AC-41EE-BD65-0AE8DA93EEEEQ30432435-071AEC43-5DFE-450D-8461-C80608E68F0AQ31046185-10394FE3-32EA-41F7-9702-4DBFF70239A4Q33576948-7EC58745-48A9-4EDA-A746-9772ED1D6CE0Q33845768-5347DA38-98BA-4C70-95D5-ED2924861C02Q33859272-025D08A2-9A05-423C-B93F-70A6AE15E686Q34506003-EBC47474-BA00-402B-9AF4-2669157AEECFQ34820000-537B8442-594C-46F1-A8EB-16E97533D950Q34920940-E01EB221-FB64-421B-BC73-455C47C98552Q35112836-635B3665-61C9-4A15-9440-36AB721650C2Q35243514-50565D6C-7913-436A-9BD1-61169C15751CQ35345300-7D1B950F-76C5-4092-AC1F-AD2707DA0780Q35400440-EB7597A6-F7D7-4BE0-944C-1B1999D8BFDCQ35490468-998BE44D-3824-41E4-9F27-8534CF036A27Q35733318-D597A05A-1E86-435F-B25A-234120F0471EQ36025907-80AB56A1-898C-4D1A-909A-25DD8CA5B313Q36054084-E5F83448-4197-43BF-BC54-061B0D107E65Q36058075-9C83114C-ACDF-485B-8FEA-3DD3B78D7F11Q36249927-DE18F16E-C812-4D6E-B574-5D7B3001E832Q36364490-F87F9D99-5435-46C6-A642-ED74EC7F58FCQ36549928-D9100256-2936-4F05-8EC4-1274775324BDQ36585261-18362B05-B8FE-4647-8768-2146A0A0A6DFQ36708879-1557B21B-82AA-46DB-9243-EDC36A0D86B3Q36896060-3A1EC0F7-0FFF-4BA8-ADFC-CBF56B2CB74EQ36928874-E289534C-0E28-412F-8EC8-40B8DA2806C4Q37067770-14039039-3454-4A43-89C2-BCAA5FF75577Q37153947-DCC6F6D2-A290-431A-B53D-1350FA8D0DCEQ37237877-24DD2A22-D3E5-454A-A0BB-B4330C5FBFC9Q37262699-B66AA8B4-FB8F-4707-AF7A-16F23604A5F7Q37498637-3D19D9A6-183A-45E7-8BDA-8EE3A99EFB8AQ37628725-68BAD4A5-5CE8-4E9D-9334-5FCAA36C43DEQ37673456-EE553FF8-3533-481C-9DA1-05D5F48FEFACQ37947698-CBBCB065-13F4-4190-8C84-BB28358AF834Q38244651-B5E85A68-155D-47F1-A464-8242E3246F26Q38643890-5953ACB1-7832-4512-AB26-DAE2246B54A7Q39039330-F54A7416-EA7E-445C-BC17-3BA691EA77DDQ40112906-C3862DDF-89E3-4369-8366-445A9A110616
P2860
Office-based management of opioid dependence with buprenorphine: clinical practices and barriers
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Office-based management of opi ...... linical practices and barriers
@en
type
label
Office-based management of opi ...... linical practices and barriers
@en
prefLabel
Office-based management of opi ...... linical practices and barriers
@en
P2093
P2860
P50
P1476
Office-based management of opi ...... linical practices and barriers
@en
P2093
Carolyn Castro-Donlan
Daniel P Alford
Julie K Alperen
Michael Botticelli
P2860
P2888
P304
P356
10.1007/S11606-008-0686-X
P577
2008-09-01T00:00:00Z